论文部分内容阅读
目的观察重组人白细胞介素-11(rhIL-11)治疗化疗所致血小板(PLT)减少的疗效和不良反应。方法采用病例自身对照研究,对第1个周期化疗(对照组)后PLT≤70×109／L的32例实体瘤患者,第2个周期(治疗组)采用相同方案化疗,化疗结束后24 h开始,皮下注射rhIL-11 25μg／kg体重,每天1次,连用7～14 d,或至PLT≥100×109／L时停药。结果治疗组化疗后各时点PLT计数均高于对照组。化疗后,治疗组和对照组PLT最低值分别为(110．2±53．5)×109/L和(55．6±46．8)×109／L,两组差异有统计学意义(P<0．01)。PLT恢复正常时间,治疗组为2～18 d,对照组为5-27 d,中位数分别为5 d和12 d,两组差异有统计学意义(P<0．01)。治疗组中PLT输注2例,次数为2次,对照组为7例9次,差异有统计学意义(P<0．01)。乏力、关节肌肉酸痛、注射部位疼痛、头痛、心悸、水肿和发热等不良反应多为Ⅰ度和Ⅱ度,可自行缓解。Ⅲ度不良反应为乏力、关节肌肉酸痛、头痛,对症处理后可缓解。结论rhIL-11是治疗化疗后PLT减少的有效药物,不良反应可以耐受。
Objective To observe the efficacy and adverse reactions of recombinant human interleukin-11 (rhIL-11) in the treatment of chemotherapy-induced reduction of platelet (PLT). Methods A case-control study was conducted in 32 patients with solid tumors with PLT ≤70 × 109 / L after the first cycle of chemotherapy (control group). The second cycle (treatment group) was treated with the same regimen. After 24 h Initially, rhIL-11 25 μg / kg body weight was injected subcutaneously once daily for 7 to 14 days or until discontinuation of PLT ≥ 100 × 109 / L. Results After treatment, the PLT count of the treatment group was higher than that of the control group. After chemotherapy, the lowest values of PLT in the treatment group and the control group were (110.2 ± 53.5) × 109 / L and (55.6 ± 46.8) × 109 / L, respectively, with significant difference between the two groups <0.01). PLT recovery time was 2 to 18 days in the treatment group and 5 to 27 days in the control group, with a median of 5 days and 12 days, respectively. There was significant difference between the two groups (P <0.01). In the treatment group, there were 2 cases of PLT infusion in 2 times and 7 cases in control group 9 times, the difference was statistically significant (P <0.01). Fatigue, joint muscle soreness, pain at the injection site, headache, palpitations, edema and fever and other adverse reactions are mostly degree Ⅰ and Ⅱ degrees, can relieve itself. Ⅲ degree adverse reactions to fatigue, joint muscle soreness, headache, symptomatic treatment can be alleviated. Conclusion rhIL-11 is an effective drug for reducing the PLT after chemotherapy, and the adverse reactions can be tolerated.